Compositions and methods for prophylaxis and treatment of addictions
View Patent ↗The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behavior and relapse practice of an addictive behavior or compulsion, by administering a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, alone or in combination with another therapeutic agent, such as, for example, an opioid receptor antagonist or an antidepressant. The present invention also includes pharmaceutical compositions for treating or preventing addiction or relapse that include a PPARγ agonist and one or more other therapeutic agents, as well as unit dosage forms of such pharmaceutical compositions, which contain a dosage effective in treating or preventing addiction or relapse. The methods and compositions of the invention are useful in the treatment or prevention of addiction to any agent, including alcohol, nicotine, marijuana, cocaine, and amphetamines, as well as compulsive and addictive behaviors, including pathological gambling and pathological overeating.
1. A method of treating an addiction to alcohol or reducing relapse addictive use of alcohol, comprising:
determining that a subject has an addiction to alcohol; and
providing to the subject an amount of an agonist of a peroxisome proliferator-activated receptor gamma (PPARγ agonist) effective for the treatment of the addiction, wherein the PPARγ agonist is a thiazolidinedione (TZD).
2. The method of claim 1 , wherein the TZD is selected from the group consisting of: pioglitazone, rosiglitazone, ciglitazone, troglitazone, englitazone, rivoglitazone and darglidazone.
3. The method of claim 2 , wherein the TZD is pioglitazone.
4. The method of claim 1 , further comprising providing an additional therapeutic agent, wherein each of the PPARγ agonist and the additional therapeutic agent contribute to the effective treatment or relapse of the addiction.
5. The method of claim 4 , wherein said additional therapeutic agent is selected from the group consisting of: an opioid antagonist, a mixed opioid partial agonist/antagonist, an antidepressant, an antiepileptic, an antiemetic, a corticotrophin-releasing factor-1 (CRF-1) receptor antagonist, a selective serotonin-3 (5-HT3) antagonist, a 5-HT2A/2C antagonist, and a cannabinoid-1 (CB1) receptor antagonist.
6. The method of claim 5 , wherein the additional therapeutic agent is an opioid antagonist selected from the group consisting of naltrexone and nalmefene.
7. The method of claim 5 , wherein the additional therapeutic agent is an antidepressant selected from the group consisting of fluoxetine, mirtazapine, and bupropion.
8. The method of claim 5 , wherein the additional therapeutic agent is an antiepileptic selected from the group consisting of benzodiazepines, barbituates, valproates, GABA agents, iminostilibenes, hydantoins, NMDA antagonists, sodium channel blockers and succinamides.
9. The method of claim 8 , wherein the additional therapeutic agent is an antiepileptic selected from the group consisting of: topiramate, levetiracetam, gabapentin, alprazolam, chlordiazepoxide, cholrazepate, clobazam, clonazepam, diazepam, halazapam, lorazepam, oxazepam, prazepam, amobarbital, mepobarbital, methylphenobarbital, pentobarbital, phenobarbital, primidone, sodium valporate, valproic acid, valproate semisodium, valpromide, losigamone, pregabalin, retigabine, rufinamide, vigabatrin, carbamazepine, oxcarbazepine, fosphenytoin sodium, mephenytoin, phenytoin sodium, harkoseramide, lamotrigine, ethosuximide, methsuximide, phensuximide, acetazolamide, briveracetam, CBD cannabis derivative, clomthiazole cdisilate, divalproex sodium, felbamate, isovaleramide, lacosamide, lamotrigine, methanesulphonamide, talampanel, tiagabine, safinamide, seletracetam, soretolide, stiripentol, sultiam, valrocemide, and zonisamide.
10. The method of claim 5 , wherein the additional therapeutic agent is a CRF-1 receptor antagonist that is antalarmin.
11. The method of claim 5 , wherein the additional therapeutic agent is a selective serotonin-3 (5-HT3) antagonist that is ondansetron.
12. The method of claim 5 , wherein the additional therapeutic agent is a cannabinoid-1 (CB-1) receptor antagonist selected from the group consisting of rimonabant and tanarabant.
13. The method of claim 5 , wherein the additional therapeutic agent is a mixed opioid agonist/antagonist that is buprenorphine.
14. A method of treating or reducing relapse use of alcohol, comprising providing an effective amount of a peroxisome proliferator-activated receptor gamma (PPARγ) agonist to a subject who has undergone a period of abstinence from, or limited or reduced use of, alcohol, wherein the PPARγ agonist is a thiazolidinedione (TZD).
15. The method of claim 14 , further comprising providing to the subject an additional therapeutic agent, wherein each of the PPARγ agonist and the additional therapeutic agent contribute to the effective reduction of the relapse use.
16. The method of claim 14 , wherein the subject previously reduced or eliminated use of alcohol in response to treatment with an effective amount of an anti-addiction treatment, and wherein the subject is no longer exposed to an effective amount of the anti-addiction treatment.
17. The method of claim 14 , wherein the TZD is selected from the group consisting of: pioglitazone, rosiglitazone, ciglitazone, troglitazone, englitazone, rivoglitazone and darglidazone.
18. The method of claim 17 , wherein the TZD is pioglitazone.
19. The method of claim 15 , wherein the additional therapeutic agent is selected from the group consisting of: an opioid antagonist, a mixed opioid partial agonist/antagonist, an antidepressant, an antiepileptic, an antiemetic, a corticotrophin-releasing factor-1 (CRF-1) receptor antagonist, a selective serotonin-3 (5-HT3) antagonist, a 5-HT2A/2C antagonist, a 5-HT2A/2C antagonist, and a cannabinoid-1 (CBI) receptor antagonist.
20. The method of claim 19 , wherein the additional therapeutic agent is an opioid antagonist selected from the group consisting of naltrexone and nalmefene.
21. The method of claim 19 , wherein the additional therapeutic agent is an antidepressant selected from the group consisting of fluoxetine, mirtazapine, and bupropion.
22. The method of claim 19 , wherein the additional therapeutic agent is an antiepileptic selected from the group consisting of benzodiazepines, barbituates, valproates, GABA agents, iminostilibenes, hydantoins, NMDA antagonists, sodium channel blockers and succinamides.
23. The method of claim 22 , wherein the additional therapeutic agent is an antiepileptic selected from the group consisting of: topiramate, levetiracetam, gabapentin alprazolam, chlordiazepoxide, cholrazepate, clobazam, clonazepam, diazepam, halazapam, lorazepam, oxazepam, prazepam, amobarbital, mepobarbital, methylphenobarbital, pentobarbital, phenobarbital, primidone, sodium valporate, valproic acid, valproate semisodium, valpromide, losigamone, pregabalin, retigabine, rufinamide, vigabatrin, carbamazepine, oxcarbazepine, fosphenytoin sodium, mephenytoin, phenytoin sodium, harkoseramide, lamotrigine, ethosuximide, methsuximide, phensuximide, acetazolamide, briveracetam, CBD cannabis derivative, clomthiazole edisilate, divalproex sodium, felbamate, isovaleramide, lacosamide, lamotrigine, methanesulphonamide, talampanel, tiagabine, safinamide, seletracetam, soretolide, stiripentol, sultiam, valrocemide, and zonisamide.
24. The method of claim 19 , wherein the additional therapeutic agent is a CRF-1 receptor antagonist that is antalarmin.
25. The method of claim 19 , wherein the additional therapeutic agent is a selective serotonin-3 (5-HT3) antagonist that is ondansetron.
26. The method of claim 19 , wherein the additional therapeutic agent is a cannabinoid-1 (CB-1) receptor antagonist selected from the group consisting of rimonabant and tanarabant.
27. The method of claim 19 , wherein the additional therapeutic agent is a mixed opioid agonist/antagonist that is buprenorphine.
28. The method of claim 15 , wherein the PPARγ agonist is pioglitazone and the additional therapeutic agent is naltrexone.
29. The method of claim 14 , wherein the relapse use is stress-induced.
30. The method of claim 16 , wherein the subject is no longer exposed to an effective amount of the anti-addiction treatment because the subject has become conditioned to the anti-addiction treatment.
31. The method of claim 16 , wherein the subject is no longer exposed to an effective amount of the anti-addiction treatment because the subject has reduced or eliminated exposure to the anti-addiction treatment.
32. A method of reducing one or more symptoms associated with physiological withdrawal from alcohol, comprising providing an effective amount of a peroxisome proliferator-activated receptor gamma (PPARγ) agonist to a subject undergoing physiological withdrawal from alcohol, wherein the PPARγ agonist is a thiazolidinedione (TZD).
33. The method of claim 32 , further comprising providing an additional therapeutic agent to a subject undergoing physiological withdrawal from an addictive agent, wherein each of the PPARγ agonist and the additional therapeutic agent contribute to reducing one or more symptoms associated with physiological withdrawal from the addictive agent.
34. The method of claim 32 , wherein the TZD is selected from the group consisting of: pioglitazone, rosiglitazone, ciglitazone, troglitazone, englitazone, rivoglitazone and darglidazone.
35. The method of claim 34 , wherein the TZD is pioglitazone.
36. The method of claim 33 , wherein the additional therapeutic agent is selected from the group consisting of: an opioid antagonist, a mixed opioid partial agonist/antagonist, an antidepressant, an antiepileptic, an antiemetic, a corticotrophin-releasing factor-1 (CRF-1) receptor antagonist, a selective serotonin-3 (5-HT3) antagonist, a 5-HT2A/2C antagonist, and a cannabinoid-1 (CB1) receptor antagonist.
37. A method of treating an addiction to alcohol, comprising:
determining that a subject has an addiction to alcohol; and
providing to the subject an amount of a thiazolidinedione (TZD) effective for the treatment of the addiction to alcohol.
38. The method of claim 37 , further comprising providing an additional therapeutic agent, wherein each of the TZD and the additional therapeutic agent contribute to the effective treatment of the addiction.